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In lung radiation therapy, the purpose of the 
planning CT scans, is to set up the patient in the 
treatment position and obtain CT images that 
simulate patient’s exact anatomical position during 
treatment to allow precise treatment planning [1].
Accurate segmentation of the normal tissue and 
tumor is necessary for good tumor treatment and 
reducing delivered dose to normal tissue all around 
tumor [2–4].
Many studies presented the benefit of using 4D 
simulation over 3D simulation in decreasing the 
PTV with possibly more benefit for smaller size 
tumors, peripherally located tumors, lower lobe 
tumors [5], and to define the respiration-induced 
tumor movement for the VMAT treatment [6]. In 
addition, using four-dimensional CT (4D-CT) can 
AbstrAct
background: The aim of the study was dosimetric effect quantification of exclusive computed tomography (cT) use with an 
intravenous (IV) contrast agent (ca), on dose distribution of 3D-crT treatment plans for lung cancer. Furthermore, dosimetric 
advantage investigation of manually contrast-enhanced region overriding, especially the heart.  
Materials and methods: Ten patients with lung cancer were considered. For each patient two planning cT sets were initially 
taken with and without ca. Treatment planning were optimized based on cT scans without ca. all plans were copied and 
recomputed on scans with ca. In addition, scans with IV contrast were copied and density correction was performed for heart 
contrast enhanced. same plans were copied and replaced to undo dose calculation errors that may be caused by ca. eventu-
ally, dosimetric evaluations based on dose volume histograms (DVhs) of planning target volumes (pTV) and organs at-risk 
were studied and analyzed using the Wilcoxon’s signed rank test.
results: There is no statistically significant difference in dose calculation for the pTV maximum, mean, minimum doses, spinal 
cord maximum doses and lung volumes that received 20 and 30 Gy, between planes calculated with and without contrast 
scans (p > 0.05) and also for contrast scan, with manual regions overriding. 
conclusions: Dose difference caused by the contrast agent is negligible and not significant. Therefore, there is no justification 
to perform two scans, and using an IV contrast enhanced scan for dose calculation is sufficient. 
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help to reduce radiation damage to the surrounding 
organ at risk (OAR) [7]. 
The accessibility to these modern imaging 
(4D-CT) and treatment (VMAT) techniques is not 
equitably offered to all lung cancer patients world-
wide, mainly because of logistic and economic in-
ter-regional disparities.
For example, in Africa, most radiotherapy cen-
ters are fairly basic. They mostly offer palliative 
services and simple curative treatments based on 
two-dimensional imaging and treatment planning. 
Approximately 80% of centers are small, with one 
or two radiotherapy machines and basic equip-
ment for imaging and treatment planning. Some 
advanced centers are equipped with modern im-
aging tools, treatment systems and more complex 
radiotherapy procedures such as three-dimen-
sional conformal radiotherapy. These centers are 
able to perform intensity-modulated radiotherapy 
and image-guided procedures. However, the latter 
account for only about 2% of radiotherapy centers 
in Africa[8]. 
Hence, in this study, the focus will be put on 
the 3D-CRT treatment. Thus, the majority of 
lung cancer treatments is done by the 3DCRT 
technique.
In three-dimensional conformal radiotherapy, 
CT images are used for creating three-dimensional 
graphics. Hounsfield Units (HU) of CT images are 
used as the basis for dose calculation and heteroge-
neity correction. CT scans may be performed with 
or without CA. 
However, using iodine contrast-enhanced com-
puted tomography in the treatment planning for 
thoracic radiation therapy, more accurate delinea-
tion of tumor and lymph nodes is attained than 
when non contrast-enhanced images are used for 
contouring. Since contrast agent helps define the 
planning target volume (PTV) and organ at risk 
region very precisely, some studies have recom-
mended intravenous CA use for planning CT scans 
[9–11].
Iodine CA, used in CT imaging, increases HU 
in tissue and becomes high density tissue for dose 
calculation [12, 13]. 
However, CA following a CT scan is excreted in 
urine, so it is only present during the CT acquisi-
tion process, and not during treatment. This may 
result in changes to patient delivered dose if dosi-
metric simulation uses CT images with a CA.
Currently, the practice of radiation therapy for 
lung cancer is to obtain two CT scans for the same 
patient, the first scan is performed without injec-
tion of CA, while the second one is carried out 
with the injection. This method was designed to 
incorporate  benefits of  intravenous contrast for 
visualizing anatomy while reducing perceived er-
rors in dose calculations that may be caused by the 
injection of CA.
The two scans (without and with CA) are fused 
and contouring of tumor volumes and organs at 
risk is done using an IV contrast scan. These two 
scans are then separated, and the planning is done 
only on scanner without contrast. Though, respira-
tory motion could influence the fusion’s precision 
between the two scans. 
However, in order to perform the simulation 
following this protocol, the patient must receive 
double exposure to radiation caused by CT scan. 
In this task, firstly we quantified and evaluat-
ed the dosimetric effects of using a contrast agent 
in the simulation of the treatment on CT scans, 
through complete dosimetric plans comparison be-
tween the two CT scans with and without a contrast 
agent. Secondly, we study the effect of a manual cor-
rection of Hounsfield unit on regions with contrast, 
especially heart, by replacing density of these high-
lighted region with the mean value of Hounsfield 
unit of the same regions in absence of contrast. The 
goal is to compare the reference plan, that we define 
as the plan computed in non-contrasted scans, with 
both dosimetric plans calculated with contrast scan 
and with contrast corrected.
Materials and methods 
In this task, ten patients with lung cancer are 
considered. A treatment planning study was con-
ducted to assess the effect of intravenous AC, dur-
ing CT planning, on the radiation dose distribution 
of 3DCRT plans. 
CT scanner data for each patient were performed 
using a General Electrical Medical Systems (OP-
TIMA CT 580) scanner with a slice thickness of 3 
mm. In addition, patients were positioned supine, 
with both arms raised to top of the head on a pul-
monary board designed to immobilize the patient. 
An initial isocenter was selected using scanner’s 
lasers. This position was marked on the patient with 
a skin tattoo.
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Two planning CTs sets that covered the total tho-
rax volume were initially taken with and without 
intravenous CA.
Contrast-less CT and contrast-enhanced CT 
scans were acquired with the same scan protocol, 
but with a delay of 50 s after injection of iodine 
contrast at 2 mL/s rate, for contrast CT scan.
After CT scans acquisition, data were trans-
ferred to the treatment planning system Eclipse 
13.6 through network. The two CT scans, with and 
without IV contrast, were fused together using fu-
sion option in the Eclipse TPS. 
The target volumes were contoured by medical 
physicians on CTs with a contrast agent. Where 
the GTV was defined as solid abnormality on CT. 
Subsequently, CTV was given as a 10 mm mar-
gin around the GTV, in which both the primary 
tumor site and levels of lymph nodes, to which 
the enlarged lymph nodes belonged, were involved. 
Remember that PTV is defined as CTV plus a 3 to 
5 mm margin and that organs at risk include the 
heart, normal lungs and spinal cord. 
Target contours and OARs have been copied 
and transferred from Enhanced Contrast CT on 
a non-contrast scan and could be refined by refer-
ring to non-contrast CT scans.
The set of contrast-enhanced CTs with contours 
will be copied, to obtain two sets of CTs with 
a contrast agent. In this second copied series, heart 
HUs will be overridden using TPS Eclipse by the 
average HUs of the heart in the non-contrast CT. 
Thus, we will have three CT scans, one without 
contrast, the second one with contrast, and the 
third one modified CT with contrast [1]. An ex-
ample of the difference between the three scans is 
shown in Figure 1. 
The PTVs of patients are treated by dose of 66 Gy 
at 2 Gy/fraction daily. The planning objectives were 
to limit prescribed dose to at least 95% of PTV with 
maximum dose at 110% of  prescribed dose. For 
all of these patient cases, planning was performed 
using multiple beams calculated using an AAA 
algorithm from Eclipse 13.6 Treatment Planning. 
Where beam weights, field-in-field technique and 
wedge angles were selected to improve dose cover-
age of the target volumes. Multi Leaf Collimators 
were used to protect OARs by minimizing the dose 
for the normal lungs [14] and heart. 
For each patient, a non-contrast scan was used as 
the reference scan set for dosimetric calculations. 
Once the plan is complete, it will be saved as a tem-
plate. Its parameters will be copied and applied to 
different data sets.
This reference plan template is copied and ap-
plied to contrast enhanced CT and contrast en-
hanced modified CT sets, with a re-optimization of 
the plan parameters, which included radiotherapy 
field sizes and leaf shapes. 
To analyze the treatment plans, isodose curves, 
DVHs of PTV and OARs were compared between 
the three plans for each patient. 
Maximum, minimum and mean dose of PTV, 
heterogeneity index (HI) and conformity index 
(CI) were basic comparison parameters.
HI and CI was defined according to RTOG defi-
nitions [15], and they are used to estimate the de-
gree of congruence between tumor contour and 
healthy tissue contour isodoses through geometric 
intersection methods [15-18]. These quality indices 
are defined as follows: 
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     (2)
where Imax is the maximum dose in the PTV, RI 
is the reference isodose (95% of prescription dose, 
ICRU50), VRI is the volume covered by the prescrip-
tion isodose and TV is the target volume.
Figure 1. right: contrast-less. center: contrast-enhanced. Left: Modified contrast-enhanced cT scan
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Moreover, the HI ideal value is 1 and increases as 
the plan becomes less homogeneous and the value 
less or equal to 2 is considered not to deviate from 
the RTOG recommendation [15]. Thereafter, the 
CI evaluates the conformity of reference isodose 
to the PTV, the CI equal to 1 relates to ideal con-
formity, and plans do not deviate from the RTOG 
recommendation if the CI value is between 1.0 and 
2.0 [15].
Analysis of OARs for each patient included the 
percentage lung volumes which received 20 and 30 
Gy (V20 and V30) to normal lung volume, respec-
tively.  
Wilcoxon sign rank test was utilized to analyze 
the differences. P-value less than 0.05 is considered 
statistically significant.
results
Agreement between contours of contrast and 
non-contrast scans fused was assessed with Dice 
Similarity Coefficient (DSC) to quantify registra-
tion accuracy [19, 20].
DSC quantifies agreement between contours ac-
cording to the degree of overlap of their volumes by 
using the following equation eq. 3.
 
𝐻𝐻𝐻𝐻 𝐻 𝐻𝐻���RI        
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𝐷𝐷𝐷𝐷𝐶𝐶 𝐻 𝑉𝑉� ∩  𝑉𝑉�(𝑉𝑉� ∪ 𝑉𝑉�)/2    
 
    (3)
Where Vd is the deformed volume and Vm is the 
reference volume. In our case Vm  corresponds to 
the contour drawn on the non-contrast scan and 
Vd corresponds to the contour on the contrast scan 
fused.
Fusion accuracy for each patient was compared 
following recommendations set forth in the TG132 
report, which recommends DSC between 0.8 and 
0.9 [21–23].
For all patients, the accuracy of the fusion 
remained within tolerances recommended by 
TG132 (Dice similarity coefficient > 0.8). Example 
of  DSC calculated for normal lungs was presented 
in Table 1.
3D-CRT main aim  is to irradiate targets with 
95% of prescribed dose. Tables 2 and 3 describe 
the comparison of PTV maximum, mean, and 
minimum doses of the contrast scan (C+) and 
the contrast scan with manual regions overriding 
(C + mdf), compared to the non-contrast plan (C–).
Regarding DVH curve (Fig. 2), it is observed 
that there are no notable changes between DVHs 
of the contrast scan and the contrast scan with re-
gions processed manually, compared to plan with-
out contrast. However, statistical analysis revealed 
no significant impact (Tab. 2 and 3) on dosimetric 
plans for minimum, mean and maximum doses of 
all plans (p > 0.05).




Mean SD Range Mean SD Range
Dmax 70.9464 1.1444 69.146–72.616 70.9481 0.9406 69.717–72.29 0.74
Dmin 49.9181 10.0780 36.598–61.97 49.8324 9.95994 37.462–61.71 0.40
Dmean 66.5869 1.3333 64.684–68.83 66.6464 1.01442 65.503–68.5 0.61
sD — standard deviation
table 2. comparison of doses calculated from non-contrast and contrast-enhanced computed tomographies (cTs)
C– C+
p-value
Mean SD Range Mean SD Range
Dmax 70.9464 1.1444 69.146–72.616 70.9739 0.9376 69.745–72.356 0.499
Dmin 49.9181 10.078 36.598–61.97 50.0213 10.0328 37.463–62.5 0.7353
Dmean 66.5869 1.3333 64.684–68.83 66.6586 1.0083 65.49–68.5 0.7353
sD — standard deviation




Dsc 0.93 0.059 0.8–0.96
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Moreover, DVHs and maximum doses to the 
spinal cord and lung volumes that received 20 and 
30 Gy (V20 and V30) are calculated and compared 
for the three scan cases. The results of the compari-
son are presented in Tables 4 and 5. The differences 
between the different cases considered are obtained 
by the Wilcoxon signed rank test.
According to the Wilcoxon test, no significant 
statistical difference was observed in terms of V20, 
V30 and mean dose to normal lungs, as well as Dmax 
calculated at the spinal cord. Figure 3 illustrates the 
obtained DVH.
Tables 6–7 recapitulate quality indices for all pa-
tients in the three scans. The comparison between 
the non-contrast plan and other plans showed no 




Mean SD Range Mean SD Range
Normal lung [Gy] 18.3177 5.77355 8.744–22.856 18.3684 4.42839 11.993–22.7 0.61
V20 (%) 30.1107 13.35027 13.071–50.22 29.8625 10.55957 18.25–47.134 0.87
V30 (%) 22.0967 7.72529 12.08–32.728 22.1981 5.86262 15.736–30.01 0.74
spinal cord Dmax 40.0617 9.97407 18.81–48.198 40.1724 10.23708 18.48–49.098 0.61
sD — standard deviation
table 5. comparison of spinal cord maximum and normal lung doses calculated from non-contrast and contrast-enhanced 
computed tomographies (cTs) with manual regions overriding
C– C+ mdf
p-value
Mean SD Range Mean SD Range
Normal lung 
Mean [Gy] 
18.3177 5.77355 8.744–22.856 18.3256 4.37785 11.99–22.4 0.87
V20 (%) 30.1107 13.35027 13.071–50.22 29.8367 10.58962 18.25–47.134 0.87
V30 (%) 22.0967 7.72529 12.08–32.728 22.6573 6.42852 15.74–30.023 0.74
spinal cord Dmax 40.0617 9.97407 18.81–48.198 40.1777 10.19213 18.6–49.093 0.75
sD — standard deviation
Figure 3. comparison of spinal cord histograms 



































Figure 2. Dose volume histograms (DVhs) comparison 
of planning target volume (pTV) for dosimetric plans  
of the three scans for one patient
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significant impact of a contrast agent or manual 
region overriding on the quality plans for CI and 
HI for all patients.
Discussion
For the purpose of this study, we examined the ef-
fects of using intravenous contrast CT scans on dose 
distribution of lung cancer 3D-RCT treatment plans 
by comparing doses calculated on non-contrast and 
contrast enhanced CTs by the same dosimetry plan, 
and estimating the degree of dose errors.
Based on a potentially remarkable difference in 
HU values for the heart, which exhibits a struc-
ture that will receive irradiation for many cases 
of patients. We examined the importance of CT 
Hounsfield number changes on contrast-affected 
regions and quantify the dosimetry effects of using 
contrast-enhanced CT scans with a contrast agent 
in treatment planning. 
We also performed an efficiency study of manual 
correction of HU regions affected by contrast and 
thus by replacing HU with its average given by 
non-contrast scanner. To increase the congruence 
between the two scans as much as possible, a com-
plete analysis of PTV and OAR dose difference is 
carried out.
Results show that using IV contrast did not lead 
to clinically significant differences in PTV coverage, 
OAR dose or Wilcoxon test p-value.
Numerous studies have addressed the impact on 
radiation dose calculations of using contrast-en-
hanced CT scans for different locations. For head 
and neck cancer, it did not result in clinically rel-
evant target dose coverage errors [24–26].
Other studies performed on lung cancer patients 
showed that the effect of IV contrast on dose cal-
culation for lung cancer treatment was negligible. 
However, these earlier studies compared and fo-
cused only on absolute differences in PTV dose 
coverage, and not on critical normal organs irradia-
tions [27–29]. 
In the present study, treatment planning was first 
made on non-contrast CT images. Then, the plans 
were copied on contrast-enhanced images, and doses 
were recalculated. A density correction was made to 
heart contrast-enhanced on IV contrast-enhanced 
scans to override possible dose calculation errors that 
may be caused by contrast-enhanced in the heart.
The results demonstrate that there are no statis-
tically significant differences on dose calculation 
between plans calculated on the non-contrast and 
contrast scans, even more on the contrast scan with 
manual regions overriding. 
So, it may not be necessary to consider the pres-
ence of IV contrast on dose calculation. This con-
firms the results of previous researchers in this 
field [27, 29]. 
It was indisputable that contrast enhanced scans 
provided clear target and critical structure projec-
tion, while avoiding doubling the patient’s dose of 
radiation caused by the scanner when taking the 
CT scan and respecting the ALARA (As Low As 
Reasonably Achievable) radiation safety principle. 




Mean SD Range Mean SD Range
cI 1.95 0.67 1.42–3.60 1.95 0.66 1.39–3.59 0.16
hI 1.13 0.15 1.10–1.16 1.13 0.13 1.11–1.15 0.67
sD — standard deviation; cI — conformity index; hI — heterogeneity index
table 7. comparison of conformity and homogeneity indices calculated from non-contrast and contrast-enhanced computed 
tomographies (cTs) with manual regions overriding
C– C+mdf
p-value
Mean SD Range Mean SD Range
cI 1.95 0.67 1.42–3.60 1.95 0.67 1.39–3.60 0.11
hI 1.13 0.15 1.10–1.16 1.12 0.13 1.11–1.15 0.51
sD — standard deviation; cI — conformity index; hI — heterogeneity index 
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Moreover, potential fusion errors are eliminated. 
Thus, there is no justification for performing two 
scans, and it will be too desirable to use the IV scan 
with enhanced contrast for dose calculation.
conclusion
In summary, the present study indicates that dif-
ferences in dose calculation between IV-contrast 
enhanced CT scans and contrast-less scans are not 
significantly remarkable in the treatment planning 
for lung cancer. However, recommendations can be 
made that just one planning CT scan with a contrast 
agent needs to be taken. That scan will not influence 
the dose calculations significantly while avoiding 
useless scans, manually overriding contrast in the 
contrast-enhanced regions, and user dependent er-
rors that can be caused by scan co-registration for 
contouring.
This recommendation may prevent patients from 
performing the scan twice, which may waste time 
and money. It is important to remember that this 
practice could prevent double exposure to x-rays 
emanating from a CT scan.
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